Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

β-thalassemia
Transfusional Iron Overload

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals